News

OnTheTrack

St. Anna CCRI research project ONTHETRRAC honored as “success story”

The ONTHETRRAC research team discovered new aspects of tumor heterogeneity and developed tools that are important for accurate diagnosis, prognosis and for overcoming treatment resistance of the nerve tumor neuroblastoma in children. In the December newsletter 2021 its work was therefore honored as a “success story” by the research promotion network European Research Area (ERA-NET). […]

St. Anna CCRI research project ONTHETRRAC honored as “success story” Read More »

Decoding the epigenome and its regulation in neuroblastoma

New FWF-grant approved: Decoding the epigenome and its regulation in neuroblastoma CONGRATS to Irfete Fetahu, PhD, postdoc at St. Anna CCRI on receiving a Stand-Alone Grant from the Austrian Science fund FWF. Together with her PI Sabine-Taschner-Mandl from the Tumor Biology group and colleagues, Irfete has the ambitious goal to decode the epigenome and its

Decoding the epigenome and its regulation in neuroblastoma Read More »

Somatic Sex – the development of malignant diseases reinterpreted

Somatic Sex – the development of malignant diseases reinterpreted How do malignant diseases develop? In his recent publication, Oskar Haas from St. Anna Children’s Cancer Research Institute suggests that the unique chromosome patterns, which define specific tumor types, arise from an accidental fusion of two normal cells – a process that simulates the fertilization of

Somatic Sex – the development of malignant diseases reinterpreted Read More »

Executive board of Europe’s neuroblastoma network SIOPEN

Sabine Taschner-Mandl is elected to the executive board of Europe’s neuroblastoma network SIOPEN Developing new therapies for childhood nerve tumors and identifying more molecular markers for better diagnosis – this is what Sabine Taschner-Mandl strives for in her new role as Executive Committee Board Member of the European Neuroblastoma Research Group SIOPEN. Sabine Taschner-Mandl, PhD,

Executive board of Europe’s neuroblastoma network SIOPEN Read More »

EU Commissioner visits St. Anna

Childhood cancer is different from cancer in adults. Thus, it needs research specifically tailored to pediatric tumors, which requires dedicated funding. The need for medicines suitable for children, as well as improvements in long-term follow-up care for cancer survivors have been discussed with EU Health Commissioner Stella Kyriakides, M.Ed., and Austrian Health Minister Wolfgang Mückstein,

EU Commissioner visits St. Anna Read More »

Kaan Boztug awarded the “Işil Berat Barlan Award”

Kaan Boztug awarded the “Işil Berat Barlan Award for Primary Immunodeficiency Diseases” The scientist receives this award for his pioneering research on immunodeficiencies. Disturbances in the balance of the immune system can be the starting point for a number of diseases such as increased susceptibility to infections, autoimmune diseases and cancer. The study of congenital

Kaan Boztug awarded the “Işil Berat Barlan Award” Read More »

Bone marrow metastases for the first time analyzed cell by cell

Bone marrow metastases for the first time analyzed cell by cell When childhood nerve tumors, so-called neuroblastomas, form metastases, they preferentially do so in the bone marrow. A study by St. Anna Children’s Cancer Research Institute shows for the first time the exact cell composition of such metastases. This knowledge forms the basis for the

Bone marrow metastases for the first time analyzed cell by cell Read More »

Four FWF Stand Alone Projects recently approved at St. Anna CCRI

Four FWF Stand Alone Projects recently approved at St. Anna CCRI The Austrian Science Fund (FWF) awards four scientists from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) with Stand Alone Grants, each of which is worth almost € 400,000. Congratulations to the grantees Kaan Boztug, Eva König, Thomas Lion, and Eleni Tomazou! Getting

Four FWF Stand Alone Projects recently approved at St. Anna CCRI Read More »

Study identifies better tolerable chemotherapy without loss of efficacy

Nerve tumor in children: study identifies better tolerable chemotherapy without loss of efficacy The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective

Study identifies better tolerable chemotherapy without loss of efficacy Read More »

a new role for histone modifications in genomic imprinting

Hot off the press: a new role for histone modifications in genomic imprinting Imprinted genes are expressed from either the paternal or maternal allele. Reporting in Nature Communications, scientists led by Martin Leeb have now discovered 71 previously unrecognized imprinted genes in preimplantation blastocysts. The study found that imprinting created by differential histone marks plays

a new role for histone modifications in genomic imprinting Read More »

Gene defect shortens survival and needs targeted treatment

Pediatric high-risk tumors: gene defect shortens survival and needs targeted treatment Neuroblastomas, the most common solid tumors outside the brain in children, are associated with poorer survival if they have genetic alterations in the ALK gene and belong to the high-risk group. This was shown by scientists from St. Anna Children’s Cancer Research institute together

Gene defect shortens survival and needs targeted treatment Read More »

WWTF grant to promote precision medicine in childhood cancer

St. Anna Children’s Cancer Research Institute is receiving a prestigious Life Science Grant for Precision Medicine, provided by the Vienna Science and Technology Fund (WWTF). Award winner Eleni Tomazou and her colleagues will clinically validate a promising new diagnostic approach, expected to enable precision medicine in childhood tumors based on blood samples.

WWTF grant to promote precision medicine in childhood cancer Read More »

Blood test detects childhood tumors based on their epigenetic profiles

Blood test detects childhood tumors based on their epigenetic profiles A new study exploits the characteristic epigenetic signatures of childhood tumors to detect, classify and monitor the disease. The scientists analyzed short fragments of tumor DNA that are circulating in the blood. These “liquid biopsy” analyses exploit the unique epigenetic landscape of bone tumors and

Blood test detects childhood tumors based on their epigenetic profiles Read More »